Palisade Bio Inc SEC Filings

Emil Chuang, a director of Palisade Bio, Inc. (PALI), was granted 18,800 phantom units on 09/04/2025. Each phantom unit equals one share of common stock and the units were granted at $0 per unit. The units vest in three equal annual installments beginning August 5, 2026, subject to continued service.

Vested phantom units will be settled solely in cash based on the fair market value of the equivalent number of shares upon termination of service, a defined liquidity change in control, or the seventh anniversary of the grant. The Form 4 reports 18,800 shares beneficially owned following the transaction and is signed by attorney-in-fact Ryker Willie on 09/05/2025.

Fragment from Palisade Bio, Inc.'s definitive proxy (DEF 14A) lists beneficial ownership counts for named individuals. The excerpt shows Donald Williams with 7,178 shares, Binxian Wei with 4,115 shares, J.D. Finley with 34,351 shares, Mitchell Jones, M.D., Ph.D., with 13,307 shares, and a total line showing 58,951 (context truncated). The table fragment also indicates that an asterisk denotes holdings that represent less than one percent. Several entries (Emil Chuang and others) show a dash or are otherwise not quantified in this excerpt. This content is a partial ownership table and does not provide broader narrative, percentages relative to outstanding shares, or transaction details.

Palisade Bio, Inc. has filed an S-3 shelf registration that lists a block of 988,872 shares, shown as 10.24% relative to the disclosed share counts. The filing shows individual holdings including Nicholas Stergis: 248,687 shares (2.65%) and Ladenburg Thalmann & Co. Inc.: 229,952 shares (2.46%), along with smaller insider holdings for David Coherd (35,125), Andrew Moorefield (17,563), and Dan Daley (2,500).

The document also discloses estimated offering expenses: Legal Fees $20,000, Accountants' Fees $17,500, and a total of $49,000. The filing is signed on August 15, 2025.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 478,945 shares of Palisade Bio, Inc. The filing states the Reporting Persons share voting and dispositive power over these shares, representing 4.99% of the outstanding common stock. Armistice Capital is disclosed as the investment manager of the direct holder, the Master Fund, and Steven Boyd is identified as the managing member of Armistice Capital. The Master Fund is described as the direct holder but disclaims beneficial ownership due to its investment management agreement with Armistice Capital. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing control.

Palisade Bio, Inc. reported interim results showing clinical progress on its lead candidate, PALI-2108, while facing tightened liquidity. The company completed dosing of 89 subjects across SAD, MAD, FE and a UC cohort in its Phase 1 study and announced positive results for the SAD/MAD/FE cohorts on May 27, 2025 and for the UC cohort on August 7, 2025. Management plans a Phase 1b cohort for fibrostenotic Crohn's disease and intends Phase 2 programs; an IND for the U.S. is anticipated in the first half of 2026.

Financially, Palisade had $5.4 million in cash and equivalents as of June 30, 2025, an accumulated deficit of $141.0 million, and recognized a net loss of $2.78 million for the quarter and $5.01 million for the six months ended June 30, 2025. The company disclosed substantial doubt about its ability to continue as a going concern for one year without additional financing. Subsequent to quarter-end, a July 2025 warrant inducement closed, generating approximately $3.9 million gross proceeds.